

- Azagury, D. M., Gluck, B. F., Harris, Y., Avrutin, Y., Niezni, D., Sason, H., & Shamay, Y. (2023). Prediction of cancer nanomedicines self-assembled from meta-synergistic drug pairs. *Journal of Control Release*. 360:418-432.
<https://doi.org/10.1016/j.jconrel.2023.06.040>
- Barenholz, Y. (2012) Doxil® – The first FDA-approved nano-drug: Lessons learned. *Journal of Controlled Release*, 160(2), 117–134.
<https://doi.org/10.1016/j.jconrel.2012.03.020>
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. *Cell*, 144(5), 646–674. [https://www.cell.com/fulltext/S0092-8674\(11\)00127-9](https://www.cell.com/fulltext/S0092-8674(11)00127-9)
- Ledet, G., & Mandal, T. K. (2012). Nanomedicine: Emerging Therapeutics for the 21st Century. *U.S. Pharmacist*, 37(3), 7-11.
<https://www.uspharmacist.com/article/nanomedicine-emerging-therapeutics-for-the-21st-century>
- Shamay, Y., Shah, J., Işık, M., Mizrachi, A., Leibold, J., Tschaharganeh, D.F., Roxbury, D., Budhathoki-Uprety, J., Nawaly, K., Sugarman, J. L., Baut, E., Neiman, M. R., Dacek, M., Ganesh, K. S., Johnson, D. C., Sridharan, R., Chu, E. L., Rajasekhar, V. K., Lowe, S. W., Chodera J.D. & Heller, D. A. (2018). Quantitative self-assembly prediction yields targeted nanomedicines. *Nature Materials* 17(4), 361–368. <https://doi.org/10.1038/s41563-017-0007-z>